We are TAE Life Sciences


We are a team of scientists, engineers, and industry experts committed to delivering transformational advances in cancer treatment technology.

TAE Life Sciences (TLS) is a medical technology company that was established to develop a break through cellular targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT) for the treatment of difficult, rapidly spreading cancers, and especially complex invasive cancers that do not respond well to standard radiation therapy.

TLS’s tandem accelerator design, neutron source and underlying technologies are based on significant investment over the past 20 years in particle accelerator R&D. TLS has applied these innovations to develop the next generation neutron irradiation system (NIS), optimized for BNCT, which could be a game changer in cancer treatment by making BNCT available and practical in a clinical setting for patients worldwide.


Enable medical advances in BNCT


Providing a new cancer treatment that extends human lives

Our Leadership Team


Bruce Bauer, PhD

Chief Executive Officer

Robert Hill

Chief Operating Officer

Kendall Morrison, PhD

Chief Science Officer

Anna Theriault

Head of Global Product Strategy and Marketing

Robert Kirby

Vice President of Regulatory Affairs

Chad Lee, PhD

Director of Clinical Development

Barry Bonner

Vice President of Business Development, Americas

Arnold Dijkstra

Vice President of Business Development, EMEA

Our Board of Directors


Bruce Bauer, PhD

Chief Executive Officer, TAE Life Sciences

Michl Binderbauer, PhD

Chief Executive Officer, TAE Technologies, Inc.

Stuart Peterson

Co-Founder and President, ARTIS Ventures

Artem Smirnov, PhD

Chief Technology Officer, TAE Technologies, Inc.

Our Advisory Board

Huan Giap, MD, PhD

Miami Sylvester Comprehensive Cancer Center

Vivek Mehta, MD

Swedish Cancer Institute

Jack Phan, MD, PhD

UT MD Anderson Cancer Center

James Welsh, MD

Loyola University, Edward Hines JR VA Hospital

Richard Amos

University College London, UK

Daniel Low

University of California, Los Angeles


Clinical Partners

A New Modality in Cancer Treatment

BNCT is vastly different approach to radiotherapy and TAE Life Sciences is dedicated to thorough clinical investigation and validation of BNCT as a new treatment modality.

We are seeking institutional partners to conduct the necessary research and clinical trials using our proprietary BNCT platform to establish efficacy and regulatory approval. Expanding your treatment options to offer hope patients who can benefit from the research we do together.

Fits Within Your Hospital

TAE Life Sciences neutron source is being designed from the ground up to fit within a hospital. Our BNCT suite will include the required drug, software and hardware components to provide our partners with an integrated BNCT suite.

Business Partners

TAE Life Sciences has established and exclusive partnership for the Chinese market with Neuboron Medtech Ltd. to exclusively provide our neutron beam system. Neuboron is the first high-tech company in China to focus on delivering a full range of solution for accelerator-based BNCT.




TAE Life Sciences (TLS) is medical equipment and biotechnology company, spun off from TAE Technologies (TAE), a global pioneer in fusion energy research. TAE has invested over $75 million in R&D on beam technology and are a significant shareholder of TAE Life Sciences and hold seats on the Board of Directors.

Technology developed by TAE, including its accelerator-based neutron source, has been adapted and validated as a neutron irradiation system (NIS) for medical use. TLS was formed to realize a novel cellular-targeted cancer treatment (CTRT), based on Boron Neutron Capture Therapy (BNCT), which currently is only available for medical research, and make it more widely available as a new cancer therapy.

TLS was launched in 2017 and is headquartered in Foothill Ranch, CA.

Our team has spent their careers in medical technology innovation, global business development, marketing, sales and financing in both early and late stage healthcare, radiation oncology, and biotechnology companies. We have global leading scientists with particle experience. We have medical device industry leaders who have broad regulatory, quality and engineering experience. Our venture backers, including ARTIS Ventures, have a deep history of financing medical technology companies.

We have raised $40m in venture capital to date. Our Series A round closed in 2017, led by ARTIS Ventures, a VC group out of San Francisco with significant success in biotechnology.

China is a strategic radiotherapy growth market and has a 5x greater incidence of head and neck cancers, which BNCT research has shown more favorable outcomes compared with other treatments. TLS has secured a Joint Venture with NeuboronMedTech, a Chinese radiotherapy company founded by Prof. Yuan Liu, one of the global leading BNCT experts.


BNCT is a targeted, non-invasive, two-step procedure designed to treat the most difficult and inoperable cancers. A patient is first infused with a non-toxic boron-10 compound, which preferentially accumulates in tumor tissue. After the infusion, the tumor is irradiated with low energy neutrons. The cells that have absorbed boron generate lithium ions and alpha particles that damage the cellular DNA and destroy cancer cells from the inside. As a result, there is minimized harm to surrounding healthy tissue not containing boron.

BNCT is radically different from other radiation delivery techniques because it is combined with the precision and accuracy of target drugs to kill cancer at the cellular level.

  • Traditional radiation using photons passes through the tumor in the body and deposits considerable amounts of energy in healthy tissue. There are also tumors that are radiosensitive or do not respond well to photon/x-ray-based radiation therapy and therefore provide poor quality outcomes for patients.
  • Newer particle radiation technology such as proton therapy have limited clinical evidence and have the potential to over dose or under dose the tumor, which could impact patients’ quality of life. These systems also have a much higher total cost of ownership.
  • BNCT uses a target drug containing boron-10 which is selectively absorbed by the cancer cells, and when irradiated with a neutron beam, initiates a reaction that emits, high-energy charged particles which have shown to systemically destroy the cancer cells with little damage to the healthy tissue.
  • BNCT does not require strict immobilization of the patient or sub-millimeter patient positioning accuracy for treatment because the target accuracy is provided by the drug.